Neuralstem, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 79   

Articles published

CUR 0.265 -0.029 (-9.99%)
price chart
Top Biotechnology Stock Picking: Neuralstem, Inc. (CUR), ChemoCentryx, Inc. (CCXI)
Neuralstem, Inc. (CUR) ended last trading session with a change of -4.72 percent. It trades at an average volume of 387.69K shares versus 1.12M shares recorded at the end of last trading session.
Upgrades And Downgrades For Neuralstem, Inc. (CUR)  Risers & Fallers
Neuralstem, Inc. (NASDAQ:CUR) Insiders Look Pessimistic About Prospects  iStreetWire
Earnings Review: Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (NASDAQ:CUR) reported earnings for the three months ended March 2016 on May 09, 2016. The company earned $-0.07 per share on revenue of $0M.
Neuralstem, Inc. (CUR) Updated Analyst Coverage  Risers & Fallers
Neuralstem Inc (CUR) Jumps 6.82% on May 26
Neuralstem Inc (CUR) was among the biggest gainers on the Russell 2000 for Thursday May 26 as the stock popped 6.82% to $0.36, representing a gain of $0.023 per share.
Brean Capital Offers Commentary on Neuralstem, Inc. Following Clinical Update ...
Brean Capital's healthcare analyst Jonathan Aschoff came out with a commentary on Neuralstem, Inc. (NASDAQ:CUR), after the company presented an updated analysis of its last completed NSI-566 Phase 1 and 2 trials in ALS at the ANA meeting in Chicago ...
Neuralstem, Inc. (CUR) Current Analyst Ratings
09/08/2014 - H.C. Wainwright began new coverage on Neuralstem, Inc. giving the company a “neutral” rating. 08/08/2014 - Neuralstem, Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 7 price target on the stock.
Neuralstem Incorporated (NASDAQ:CUR) Short Interest Decreased By 1.44%  HNN
Stock Update (NYSEMKT:CUR): Neuralstem, Inc. Reports Third Quarter 2015 ...
Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company leveraging its unique human neural stem cell-derived platform to identify and develop novel neurogenic therapies for diseases of the central nervous system (CNS), today reported its financial ...
Neuralstem, Inc. (NYSE:CUR) Given $4.08 Consensus Target Price by Brokerages
Neuralstem logo Shares of Neuralstem, Inc. (NYSE:CUR) have received an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports.
Tuesday Pre-Market Insights: Northwest Biotherapeutics, Inc (NWBO), Neuralstem ...
Neuralstem, Inc. (NASDAQ:CUR) is falling over 37% in pre-market trading after the company announced a proposed public offering of common stock of 20,000 shares at $0.40 per share.
Neuralstem Inc.: Neuralstem Announces New Chairman and Further Reorganization ...
GERMANTOWN, Md., June 13, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced, ...
Shining on Major News: Neuralstem, Inc. (NASDAQ:CUR), SunPower Corporation ...  Benchmark Monitor
Neuralstem Shares Bounce As CEO Takes On Chairman Role (NASDAQ:CUR)  Sonoran Weekly Review
Sell-Side Recommendation & Price Target Projections on Neuralstem, Inc ...
Investors are continuously striving to keep on top of the latest sentiment on Neuralstem, Inc. (NASDAQ:CUR) stock. Many investors will follow the opinions of Wall Street equity analysts that routinely cover the stock.